Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Sells $474,045.00 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Carlo Incerti sold 16,500 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $28.73, for a total value of $474,045.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Dyne Therapeutics Price Performance

DYN stock traded up $0.95 during midday trading on Monday, reaching $29.34. 1,268,326 shares of the company’s stock traded hands, compared to its average volume of 1,493,931. The company has a market capitalization of $2.99 billion, a P/E ratio of -8.24 and a beta of 1.10. Dyne Therapeutics, Inc. has a fifty-two week low of $10.03 and a fifty-two week high of $47.45. The business has a 50-day moving average price of $32.42 and a two-hundred day moving average price of $35.26.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). As a group, research analysts forecast that Dyne Therapeutics, Inc. will post -3.39 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on DYN shares. JPMorgan Chase & Co. downgraded shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $43.00 to $35.00 in a report on Thursday, October 24th. Oppenheimer restated an “outperform” rating and set a $55.00 target price on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. Stifel Nicolaus raised their target price on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a report on Friday, August 16th. Chardan Capital restated a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Finally, Piper Sandler restated an “overweight” rating and set a $53.00 target price on shares of Dyne Therapeutics in a report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $51.40.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in DYN. Nisa Investment Advisors LLC lifted its position in shares of Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after purchasing an additional 669 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Dyne Therapeutics during the third quarter worth $34,000. Point72 DIFC Ltd acquired a new position in shares of Dyne Therapeutics during the third quarter worth $36,000. US Bancorp DE lifted its position in shares of Dyne Therapeutics by 776.9% during the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new position in shares of Dyne Therapeutics during the third quarter worth $62,000. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.